• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    President and CEO Altman Peter bought $2,989 worth of shares (1,700 units at $1.76), increasing direct ownership by 1% to 167,562 units (SEC Form 4)

    8/11/25 7:21:14 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCDA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Altman Peter

    (Last) (First) (Middle)
    C/O BIOCARDIA, INC.
    320 SOQUEL WAY

    (Street)
    SUNNYVALE CA 94085

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BioCardia, Inc. [ BCDA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    08/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/11/2025 P 1,700(1) A $1.758(1) 167,562 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This transaction was executed in multiple trades ranging from $1.73 to $1.82 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.
    /s/ David McClung, by power of attorney 08/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BCDA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCDA

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stertzer Simon H bought $498,000 worth of shares (398,400 units at $1.25) (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    9/23/25 9:00:48 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Blank Andrew Scott bought $360,000 worth of shares (288,000 units at $1.25) (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    9/23/25 9:00:29 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $60,000 worth of shares (48,000 units at $1.25), increasing direct ownership by 28% to 216,762 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    9/23/25 9:00:09 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stertzer Simon H bought $498,000 worth of shares (398,400 units at $1.25) (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    9/23/25 9:00:48 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Blank Andrew Scott bought $360,000 worth of shares (288,000 units at $1.25) (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    9/23/25 9:00:29 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $60,000 worth of shares (48,000 units at $1.25), increasing direct ownership by 28% to 216,762 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    9/23/25 9:00:09 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioCardia Regains Compliance with Nasdaq Listing Requirements

    SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance with the Nasdaq Capital Market's Listing Requirements (the "Listing Requirements"). This confirmation follows the Company's successful efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates and advance its approved products. Specifically, on October 1, 2025, BioCardia received written notice (the "Notice") from Nasdaq confirming that the Nasdaq Staff has determined the Company complies with L

    10/2/25 8:00:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure

    SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has had a positive preliminary clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on the CardiAMP Heart Failure Trial results previously provided to the agency. The meeting was held in preparation for the formal clinical consultation on acceptability of the clinical data for submission of an application for approval. PMDA requested additional details including clarification on positioning of the prespecified composite endpoints, background on s

    9/22/25 8:00:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Announces Pricing of Up To $12 Million Public Offering

    SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA) ("BioCardia" or the "Company"), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the pricing of a public offering of an aggregate of 4,800,000 shares of its common stock and short-term warrants to purchase up to 4,800,000 shares of common stock, at a combined public offering price of $1.25 per share and accompanying short-term warrant. The short-term warrants will have an exercise price of $1.25 per share, will be exercisable upon issuance and will expire two years thereafter. The closing of the offering is expected to occur o

    9/18/25 9:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    SEC Filings

    View All

    BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BioCardia, Inc. (0000925741) (Filer)

    10/2/25 8:00:10 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - BioCardia, Inc. (0000925741) (Filer)

    9/24/25 8:00:13 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BioCardia, Inc. (0000925741) (Filer)

    9/22/25 8:00:10 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on BioCardia with a new price target

    HC Wainwright & Co. initiated coverage of BioCardia with a rating of Buy and set a new price target of $9.00

    12/20/21 6:05:04 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia downgraded by Dawson James

    Dawson James downgraded BioCardia from Buy to Neutral

    4/16/21 7:22:02 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Financials

    Live finance-specific insights

    View All

    BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2025 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic hear

    8/11/25 9:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

    SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2025 by conference call on Monday, August 11, 2025 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10201553/ff96e5f036. Please note that registered participants will receive their dial-in number upon registration. For those who have not

    8/6/25 3:18:21 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fra

    5/14/25 4:05:00 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioCardia Inc.

    SC 13G - BioCardia, Inc. (0000925741) (Subject)

    9/6/24 7:45:48 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

    SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

    4/5/24 4:13:08 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

    SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

    2/27/24 4:53:40 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care